Login / Signup

Eligibility for antiamyloid treatment: preparing for disease-modifying therapies for Alzheimer's disease.

Chu-Yueh GuoKatherine PattersonReshad MalikUttara MandalHina AsifRos HumphreysMichael PayneEng O-CharoenratLauren HuzzeyAdam ClareKate GreenMaija MortonCatrin SohrabiNavreen SinghAmirtha PasupathyMilan PatelSam WhitemanKate MaxminNicholas BassBhavya GuptaClaudia CooperCharles R MarshallRimona Sharon WeilCatherine J Mummery
Published in: Journal of neurology, neurosurgery, and psychiatry (2024)
While a sizeable proportion of patients attending memory clinics may be referred for triaging for DMTs for AD, only a minority are likely to be suitable for these, as demonstrated in patients seen in specialist cognitive services. This will need to be considered when designing pathways for DMT delivery.
Keyphrases
  • end stage renal disease
  • ejection fraction
  • newly diagnosed
  • chronic kidney disease
  • primary care
  • healthcare
  • prognostic factors
  • mental health
  • working memory
  • patient reported
  • smoking cessation